Marshall Wace
TELO icon

Marshall Wace’s Telomir Pharmaceuticals TELO Stock Holding History

Marshall Wace’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75,770
Closed -$94.7K – 3501
2025
Q2 		$94.7K Buy
+75,770
New +$175K ﹤0.01% 2548

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace's TELO Position: Q3 2025 in Review

Marshall Wace sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 75,770 shares — an estimated $94.7K sold.

Marshall Wace first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $94.7K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • Marshall Wace reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 75,770 Telomir Pharmaceuticals shares in Q3 2025, an estimated $94.7K.
  • Marshall Wace first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Marshall Wace's Telomir Pharmaceuticals position peaked at $94.7K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.